Tirzepatide offers superior glycemic control compared with insulin, irrespective of baseline levels: Study
USA: The post hoc analyses of the SURPASS-3 and SURPASS-4 trials revealed superior glycemic control with tirzepatide compared with insulin in patients with type 2 diabetes (T2D), regardless of baseline glycemic pattern. The findings were published online in Diabetes Care on March 26, 2024 “Treatment with tirzepatide was consistently associated with more reduced postprandial glucose […]